U.S. Markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.42
    -0.33 (-1.44%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.3402%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.4286%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.1613%)
     
  • BTC-USD

    47,445.57
    -1,200.92 (-2.47%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) showed the treatment slowed cognitive, functional, and behavioral decline in the early stages of the disease.

  • Treatment effects were exhibited across all three cognitive and three functional domains measured by Clinical Dementia Rating-Sum of Boxes (CDR-SB), the EMERGE study's primary endpoint.

  • Treatment effects were observed across Alzheimer's Disease Assessment Scale – Cognitive Subscale (ADAS-Cog13) items sensitive to cognitive change in early symptomatic Alzheimer's secondary endpoint measures.

  • Aduhelm was also associated with reducing behavioral and psychiatric symptoms of Alzheimer's disease, as measured by the Neuropsychiatric Inventory-10 (NPI-10), a tertiary endpoint.

  • Also, data analyses demonstrated a positive association between aducanumab treatment effect on brain amyloid-beta plaques and clinical measures across dose groups, except for the high-dose group.

  • A greater reduction in brain plaque levels was also associated with a greater reduction in cerebrospinal fluid (CSF) markers of tau and neurodegeneration and less decline on clinical endpoints.

  • Additionally, the third analysis showed that a smaller magnitude of clinical decline was observed in patients whose brain plaque levels were lowered to a threshold considered to be amyloid negative relative to patients who did not reach this threshold.

  • Price Action: BIIB shares closed at $331.93, and ESALY shares closed at 86.34 on Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.